Journal Article

Use of Rifabutin with Protease Inhibitors for Human Immunodeficiency Virus-Infected Patients with Tuberculosis

Masahiro Narita, Jerry J. Stambaugh, Elena S. Hollender, Denis Jones, Arthur E. Pitchenik and David Ashkin

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 30, issue 5, pages 779-783
Published in print May 2000 | ISSN: 1058-4838
Published online May 2000 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/313771
Use of Rifabutin with Protease Inhibitors for Human Immunodeficiency Virus-Infected Patients with Tuberculosis

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Drug interactions between rifamycins and highly active antiretroviral therapy (HAART) have raised concerns in the treatment of human immunodeficiency virus (HIV)-infected patients with tuberculosis. We conducted a study of this interaction by measuring serum drug levels of all HIV-infected patients with tuberculosis who were admitted to A. G. Holley State Tuberculosis Hospital (Florida) from October 1997 through December 1998, who were concomitantly treated with rifabutin and HAART. All 25 patients studied became culture-negative within 2 months of initiation of therapy for tuberculosis and remained negative for a median of 13 months follow-up after completion of therapy. HIV viral loads (mean ± SEM) decreased significantly from 4.95 ± 0.21 log10 copies/mL before initiation of HAART to 2.77 ± 0.07 log10 copies/mL before discharge (P < .001); 20 of 25 patients achieved viral loads of <500copies/mL. In summary, the concomitant use of rifabutin and HAART can lead to successful treatment of HIV-infected patients with tuberculosis without increased side effects.

Journal Article.  3244 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.